Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Atopic dermatitis

Empirical data with dupilumab confirm the empirical evidence

    • Congress Reports
    • Dermatology and venereology
    • RX
    • Studies
  • 4 minute read

The biologic Dupilumab has proven itself under “real-life” conditions and has already received an extension of approval in the EU for the age group 12 years and older. At the SGDV annual meeting, experts provided information on the current state of research.

The recombinant human IgG4 monoclonal antibody dupilumab, approved in Switzerland for moderate to severe atopic dermatitis in adults since this year, inhibits signal transduction of IL4 and IL13, two key cytokines in the inflammatory process. In the phase III LIBERTY AD CHRONOS trial, 69% of subjects treated with dupilumab achieved at least EASI-75, significantly more than in the placebo condition (p<0.0001) [1,2] (Fig. 1).

 

 

Positive “real life” interim balance sheet

Registry data from Germany of adult patients with atopic dermatitis who are suitable for system therapy show a positive picture for dupilumab under “real-life” conditions [1]. Longitudinal studies are currently underway to monitor newly initiated systemic therapies. An interim evaluation after three months with more than 100 patients showed that an improvement in EASI75 was measurable in 57% of patients, which was a positive result, the speaker said [1]. In the EU, where Dupixent® has already been approved for adults with moderate to severe atopic dermatitis since 2017, a marketing authorization extension for adolescents aged 12 years and older was recently granted [3].

The drug is very easy to handle in practice: the recommended dosage of Dupixent® in adults is an initial dose of 600 mg as a subcutaneous injection (two injections of 300 mg each), followed by a dose of 300 mg as a subcutaneous injection every two weeks [4]. It is explicitly stated that topical therapy should not be suspended when starting systemic therapy with dupilumab. In cases of patients suffering from asthma in addition to atopic dermatitis treated with oral corticosteroids, the steroid dose can be reduced [4], the speaker explained. However, it is important to keep this in mind when discontinuing dupilumab therapy and to advise the patient to readjust the steroid dose [1]. Regarding treatment of possible side effect of atypical dupilumab-induced conjunctivitis, which is a different type of ocular inflammation than allergic conjunctivitis, Prof. Werfel and colleagues recommend the following [5]: 1. eyelid margin care and tear substitute, 2. prescribe eye drops (fluorometholone or hydrocortisone), 3. if symptoms do not heal: Refer to ophthalmologist who can prescribe eye drops containing ciclosporin. In the technical information resp. the package leaflet also lists oral herpes as a common side effect. Prof. Werfel is critical of this assessment because this side effect was also common in placebo groups. With regard to eczema herpeticatum, the risk is not increased but is reduced by about 60%, emphasizes Prof. Werfel [6].

Guideline recommendation as first-line therapeutic emotion

Dupilumab and ciclosporin are recommended in current guidelines as first-line systemic therapeutics for chronic moderate to severe atopic dermatitis in adults [7–9]. Methotrexate, azathioprine, and mycophenolate mofetil can be used as off-label preparations. Systemic glucocorticosteroids are not indicated as long-term therapy (>3 weeks); these should only be used in the short term for acute episodes, the speaker explained [1]. Specific immunotherapy plays a minor role in atopic dermatitis according to current knowledge. The authors of a Cochrane meta-analysis concluded that there is limited evidence for the efficacy of spcific immunotherapy (SIT) in atopic dermatitis. However, it could be clearly proven that SIT in the indication of pollen sensitization and atopic dermatitis does not harm, i.e. it does not lead to a worsening of the atopic symptoms.

Translational research has more arrows in its quiver

Currently, several studies are underway to investigate the efficacy and safety of additional immunomodulatory agents in atopic dermatitis. According to Prof. Werfel, some of these have a good chance of achieving market approval in the coming years:

anti-IL13 antibodies: Representatives of this substance class act more specifically than dupilumab and attack only one of the two cytokines. Tralokinumab has shown good efficacy in studies to date; nearly 50% achieved EASI75 at 12 weeks at the 150 mg dose [1].

Janus kinase 1 and 2 inhibitors: According to current data, there is a very rapid onset of action, with very good effects measurable after just four weeks [1]. Baricitinib is already currently available in Germany in rheumatology, said Prof. Werfel. He has high hopes that approval will be granted for the indication of atopic dermatitis.

anti-IL31 antibody and anti-TSLP: IL31 and TSLP are cytokines that both act as mediators of inflammation and are involved in itch [1]. Studies on efficacy in atopic dermatitis are not yet very advanced, he said.

Histamine-4 receptor antagonists: Like the two candidate molecules IL31 and TSLP, histamine-4 has a dual function in the pathomechanism of atopic dermatitis (inflammatory mediator, itch mediator). Currently, a large phase IIb trial is underway to investigate efficacy [1]. According to current knowledge, histamine-4 receptor blockers are more effective in atopic dermatitis than histamine-1 receptor and histamine-2 receptor antagonists.

Source: SGDV, Basel

 

Literature:

  1. Werfel T: Atopic dermatitis – newest therapeutic approaches for practice, Key Lecture 4, slide presentation, Prof. Dr. med. Thomas Werfel, Hannover Medical School, SGDV Annual Meeting, Basel 20.09.2019.
  2. Blauvelt A, et al: Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017 Jun 10; 389(10086): 2287-2303. doi: 10.1016/S0140-6736(17)31191-1. epub 2017 May 4.
  3. EMA: Dupixent®, www.ema.europa.eu/en/medicines/human/summaries-opinion/dupixent-0
  4. Dupixent® 300 mg: Expert information, https://compendium.ch
  5. Wohlrab J, Wollenberg A, Reimann H, et al: Interdisciplinary recommendation for action in dupilumab-associated ocular inflammatory disease. Der Hautarzt 2019; 70(1): 64-67.
  6. Fleming P: Risk of infection in patients with atopic dermatitis treated with dupilumab: A meta-analysis of randomized controlled trials. JAAD 2018; 78(1): 62-69.e1, https://doi.org/10.1016/j.jaad.2017.09.052
  7. AMWF: Guideline “Neurodermatitis”, www.awmf.org/leitlinien/detail/ll/013-027.html
  8. Werfel T. et al: S2k-Leitlinie Neurodermitis [atopic eczema; atopic dermatitis] Kurzversion, JDDG 2016, https://onlinelibrary.wiley.com/doi/abs/10.1111/ddg.140_12871
  9. European Dermatology Forum: EDF-Guidelines for Treatment of Atopic Eczema (Atopic Dermatitis) Part I, www.isplad.org/wp-content/uploads/2018/03/linee_guida_eczema_atopico.pdf

 

DERMATOLOGIE PRAXIS 2019; 29(5): 30-31 (published 10/10/19, ahead of print).

Autoren
  • Mirjam Peter, M.Sc.
Publikation
  • DERMATOLOGIE PRAXIS
Related Topics
  • Atopic dermatitis
  • Dupilumab
  • dupixent
Previous Article
  • Breast Cancer

BRCA mutations and their consequences

  • Gynecology
  • Market & Medicine
  • Oncology
  • RX
View Post
Next Article
  • Type 2 diabetes

Multifactorial goal-directed therapy for under-50s.

  • Congress Reports
  • Endocrinology and Diabetology
  • General Internal Medicine
  • Partner Content
  • RX
  • Studies
View Post
You May Also Like
View Post
  • 5 min
  • New findings on known forms of therapy

Fatigue syndrome as a leading symptom in multiple sclerosis

    • Education
    • Neurology
    • Pharmacology and toxicology
    • RX
    • Studies
View Post
  • 5 min
  • Asthma in adults

When do pneumology specialists come into play?

    • RX
View Post
  • 10 min
  • Cutaneous lupus erythematosus

From diagnostic workup to successful treatment

    • Congress Reports
    • Dermatology and venereology
    • RX
    • Studies
View Post
  • 4 min
  • Guideline update

Dietary recommendations for Crohn’s disease and colitis

    • Education
    • Gastroenterology and Hepatology
    • General Internal Medicine
    • Nutrition
    • RX
    • Studies
View Post
  • 4 min
  • Circadian rhythm during Ramadan

Disturbed sleep patterns lead to metabolic stress

    • Education
    • Endocrinology and Diabetology
    • General Internal Medicine
    • Nutrition
    • RX
    • Studies
View Post
  • 6 min
  • Case Report

Breast cancer metastases in the bladder

    • Cases
    • Education
    • Gynecology
    • Oncology
    • RX
    • Urology
View Post
  • 11 min
  • Findings from the ALS Symposium 2024 in Montreal

Current and future approaches in the treatment of amyotrophic lateral sclerosis (ALS)

    • Congress Reports
    • Interviews
    • Neurology
    • RX
    • Studies
View Post
  • 8 min
  • Efficacy, mechanism of action and clinical effects

Garlic and high blood pressure

    • Cardiology
    • Education
    • General Internal Medicine
    • Pharmaceutical medicine
    • Phytotherapy
    • RX
    • Studies
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Patience, knowledge and persistence in therapy
  • 2
    Sarcopenia and malnutrition in the context of pneumological rehabilitation
  • 3
    Medical and psychosocial perspectives
  • 4
    New nomenclature for non-alcoholic fatty liver disease
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.